PROM1 and breast cancer: Moreover, CD44+/CD24−/ALDH1+ MDA-MB-231 and CD44+/CD133−/ALDH1+ MDA-MB-468 BC cells demonstrated stronger tumorigenic and metastatic capabilities than ALDH1lowCD44low BC cells (Croker et al., 2009).